A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel, Dose-Ranging Study to Evaluate The Efficacy, Safety, Tolerability, and Pharmacodynamics of NBI-6024 In Adult and Adolescent Patients With New Onset Type 1 Diabetes Mellitus
Latest Information Update: 17 Sep 2021
At a glance
- Drugs NBI-6024 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
Most Recent Events
- 09 Apr 2009 New trial record